anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intestinal fibrosis, a severe complication of Crohn's disease (CD), is characterized by excessive extracellular matrix (ECM) deposition and induces intestinal strictures, but there are no effective antifibrosis drugs available for clinical application. We performed single-cell RNA sequencing (scRNA-Seq) of fibrotic and nonfibrotic ileal tissues from patients with CD with intestinal obstruction. Analysis revealed mesenchymal stromal cells (MSCs) as the major producers of ECM and the increased infiltration of its subset FAP+ fibroblasts in fibrotic sites, which was confirmed by immunofluorescence and flow cytometry. Single-cell transcriptomic profiling of chronic dextran sulfate sodium salt murine colitis model revealed that CD81+Pi16- fibroblasts exhibited transcriptomic and functional similarities to human FAP+ fibroblasts. Consistently, FAP+ fibroblasts were identified as the key subtype with the highest level of ECM production in fibrotic intestines. Furthermore, specific knockout or pharmacological inhibition of TWIST1, which was highly expressed by FAP+ fibroblasts, could significantly ameliorate fibrosis in mice. In addition, TWIST1 expression was induced by CXCL9+ macrophages enriched in fibrotic tissues via IL-1β and TGF-β signal. These findings suggest the inhibition of TWIST1 as a promising strategy for CD fibrosis treatment.
BACKGROUND: This study aims to explore the impact of using visual display terminal (VDT) on the visual fatigue of operators through meta-analysis.
METHODS: The terms "VDT", "visual fatigue", "eyestrain", and "viewing distance" were selected from the Wangfang, China National Knowledge Infrastructure (CNKI), Web of Science, Springer, and Science Direct online databases. The retrieval time was from the establishment of the database to the present. All clinical studies related to the analysis of the effects of VDT use on visual fatigue were available. The included studies were screened, and after quality assessment, basic data and outcome index data were extracted. The count data were represented by relative risk (RR) and 95% confidence interval (CI). The measurement data were represented by the mean value (MD), standard deviation (SD), and 95% CI. Review Manager 5.3 (RevMan5.3) was employed to analyze the included indicators. Funnel plots were drawn using RevMan5.3 to analyze potential publication bias. The incidence of visual fatigue, lens use time, blink interval, and other indicators were compared between the VDT group and the control (Ctrl) group. Meanwhile, the incidence of eye fatigue and blurred vision in the two groups was counted.
RESULT: The incidence of eye pain, fatigue, blurred vision, teary eyes, and dry eyes in the VDT group significantly exceeded that in the Ctrl group. Meanwhile, the dry eye score, as well as the scores for eye fatigue, discomfort, and blurred vision, were significantly higher in the VDT group compared to the Ctrl group.
CONCLUSIONS: The results indicate that the use of VDT has a significant impact on visual fatigue.
The eubiotic product, according to the invention, is constituted of a mixture of three Lactobacillus acidophylus LR, LV and LD strains, registered in the Biosan Centre Collection Bucharest under the nos. 13, 17 and 11, the association being in equal parts of each strain before lyophilisation of mixture. The Lactobacillus acidophylus LD-11 strain ferments the raffinose. The Lactobacillus acidophylus LR-13 strain ferments the trehalose. The Lactobacillus acidophylus LV-17 strain ferments the dextrine. The three associated lactic bacilli strains are used as active ingredients in different cosmetic forms for the maintenance and treatment of teguments, the product being included in amount of 1-10 g under lyophilised form at 100 g of cosmetic product.
BACKGROUND: Terrible triad of the elbow (TTE) is a complex dislocation associating radial head (RH) and coronoid process (CP) fractures. There is at present no reproducible anatomic model for TTE, and pathophysiology is unclear. The main aim of the present study was to create and validate an anatomic model of TTE. Secondary objectives were to assess breaking forces and relative forearm rotation with respect to the humerus before dislocation.
METHODS: An experimental comparative study was conducted on 5 fresh human specimens aged 87.4 ± 8.6 years, testing 10 upper limbs. After dissection conserving the medial and lateral ligaments, interosseous membrane and joint capsule, elbows were reproducibly positioned in maximal pronation and 15° flexion, for axial compression on a rapid (100 mm/min) or slow (10 mm/min) protocol, applied by randomization between the two elbows of a given cadaver, measuring breaking forces and relative forearm rotation with respect to the humerus before dislocation.
RESULTS: The rapid protocol reproduced 4 posterolateral and 1 divergent anteroposterior TTE, and the slow protocol 5 posterolateral TTE. Mean breaking forces were 3,126 ± 1,066 N for the lateral collateral ligament (LCL), 3,026 ± 1,308 N for the RH and 2,613 ± 1,120 N for the CP. Comparing mean breaking forces for all injured structures in a given elbow on the rapid protocol found a p-value of 0.033. Comparison of difference in breaking forces in the three structures (LCL, RH and CP) between the slow and rapid protocols found a mean difference of -4%. Mean relative forearm rotation with respect to the humerus before dislocation was 1.6 ± 1.2° in external rotation.
CONCLUSIONS: We create and validate an anatomic model of TTE by exerting axial compression on an elbow in 15° flexion and maximal pronation at speeds of 100 and 10 mm/min.
LUM/IVA granules or tablets were administered orally every 12 hours (Participants aged 2 through 5 years received LUM 100 mg/IVA 125 mg granules or LUM 150 mg/IVA 188 mg granules based on body weight. Participants ≥6 years of age were to receive LUM 200 mg/IVA 250 mg tablets). Doses were adjusted upward for changes in weight and age.
Since the beginning of the COVID-19 pandemic in March 2020, more than 160 million people have suffered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and more than 3 million deaths occurred. Currently, two vaccines using messenger RNA (mRNA) technology and lipid nanoparticle (LNP) delivery systems have been approved for emergency use by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA): mRNA-1273, Moderna, and BNT162b2, Pfizer. In phase-3 clinical trials, two injections of these vaccines, spaced 21 and 28 days apart, showed efficacy higher than 90% in preventing symptomatic infections. The reported humoral immunity response with the mRNA vaccines was similar to that elicited by convalescent serum obtained from patients who recovered from Covid-19 infection. However, the T-cell mediated reaction to these vaccines remains to be fully elucidated. Diabetic patients are at higher risk of developing severe SARS-CoV-2 infection. In a large observational cohort study, the overall risks of fatal or critical care unit-treated COVID-19 were significantly elevated for patients with diabetes compared with the general population. While patients with Type 2 diabetes (T2D) are usually older and with a higher comorbidity index, the altered immune functions seem to play a major role in patients with Type 1 Diabetes (T1D). Altough an impaired immune response to vaccination was hypothesized in diabetic patients, no evidence has been provided. Given the high risk of severe SARS-CoV-2 infection, patients with T1D and T2D should represent a priority group to receive the COVID-19 vaccine. There are currently no studies on diabetic population response to mRNA COVID-19 vaccines. Therefore, in this observational cohort study, investigators will retrospectively analyze the safety and immunogenicity of the mRNA vaccines in eliciting both the humoral and cellular immune response in a subset of patients with T1D, T2D and in non-diabetic individuals who already underwent blood sampling for measuring humoral response against SARSCoV2 for healthcare purposes and based on the clinical practice guidelines.
PURPOSE OF REVIEW: Kidney fibrosis is a key pathological aspect and outcome of chronic kidney disease (CKD). The advent of multiomic analyses using human kidney tissue, enabled by technological advances, marks a new chapter of discovery in fibrosis research of the kidney. This review highlights the rapid advancements of single-cell and spatial multiomic techniques that offer new avenues for exploring research questions related to human kidney fibrosis development.
RECENT FINDINGS: We recently focused on understanding the origin and transition of myofibroblasts in kidney fibrosis using single-cell RNA sequencing (scRNA-seq) [1] . We analysed cells from healthy human kidneys and compared them to patient samples with CKD. We identified PDGFRα+/PDGFRβ+ mesenchymal cells as the primary cellular source of extracellular matrix (ECM) in human kidney fibrosis. We found several commonly shared cell states of fibroblasts and myofibroblasts and provided insights into molecular regulators. Novel single-cell and spatial multiomics tools are now available to shed light on cell lineages, the plasticity of kidney cells and cell-cell communication in fibrosis.
SUMMARY: As further single-cell and spatial multiomic approaches are being developed, opportunities to apply these methods to human kidney tissues expand similarly. Careful design and optimisation of the multiomic experiments are needed to answer questions related to cell lineages, plasticity and cell-cell communication in kidney fibrosis.
No treatment for 6 months followed by optional treatment with JUVÉDERM VOLUMA® XC injected into the chin at a volume determined by the investigator on Month 6. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 mL for both treatments combined.
PURPOSE:The titled bath preparation having synergistically raised promoting effect on circulation of the blood and skin touch such as smooth feeling, etc., obtained by adding an enzyme to a bath preparation comprising a carbonate and an acid, making hot water in a bath show weakly acidic pH when it is used. CONSTITUTION:5-80wt% carbonate (e.g., NaHCO3, Na2CO3, KHCO3, K2CO3, etc.) is blended with an acid (e.g., organic acid such as formic acid, acetic acid, etc., or aliphatic dicarboxylic acid such as succinic acid, etc.) in a ratio (0.01wt% aqueous solution of the bath preparation shows 4-7pH, especially preferably 6.0-6.7pH) to make hot water in a bath show weakly acidic pH, and mixed with 0.001-10wt% enzyme (e.g., protease derived from pepsin, tryptophan, mold, yeast, etc.), to give a weakly acidic bath preparation. The bath preparation may be blended with a perfume, a vitamin, a crude drug, or its extracted essence, etc., to raise further the effects. In the preparation, CO2 exists as molecules in an acidic range and has promoting effect on blood circulation of the skin.
A system includes a processor circuit configured for communication with an external imaging device. The processor circuit receives, from the external imaging device, an image comprising a blood vessel within a patient. The processor circuit determines, using the image, a first location of the blood vessel with a restriction in blood flow caused by compression of the blood vessel by an anatomical structure within the patient and different than the blood vessel. The processor circuit generates a first graphical representation associated with the restriction. The processor circuit outputs, to a display in communication with the processor circuit, a screen display. The screen display includes the image and the first graphical representation at the first location of the blood vessel in the image.
Immediately following mastectomy, participants will undergo prepectoral reconstruction approach. Intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities. Participants will be evaluated at 6 time points during the study.
One group receives 8 weeks of active T-PEMF treatment and another group receives 8 weeks of placebo T-PEMF. Both treatments to be performed 30 minutes once a day.
The present invention discloses a process for preparing 12-dehydroxy azithromycin. Erythromycin c is catalyzed by methylase to generate erythromycin B, and then the erythromycin B and hydroxylamine hydrochloride are processed by reflux for 15 to 25 hours in methanol to prepare erythromycin B. in acetone, baker (Beckmann) is rearranged to prepare erythromycin B imine ether. Aza erythromycin B is prepared by the reduction and hydrogenization by using a catalyst in ethanol. A 12-dehydroxy azithromycin raw material is prepared by the methylation processing in an organic solvent. The medicine belongs to broad-spectrum antibacterial medicine, has good antibacterial activity to most of gram-negative bacteria, intracellular pathogenic bacteria, mycoplasma, chlamydia, etc. and has certain antibacterial activity to gram positive bacteria. The development and the utilization of the medicine have good function for curing diseases of human bodies and keeping health.
Administer HETLIOZ capsules and HETLIOZ LQ oral suspension without food [see Clinical Pharmacology (12.3)].

If a patient is unable to take HETLIOZ at approximately the same time on a given night, they should skip that dose and take the next dose as scheduled.

HETLIOZ LQ Oral Suspension

See "Instructions for Use" for complete administration instructions.

Shake HETLIOZ LQ oral suspension well for at least 30 seconds before every administration. Remove seal and insert press-in bottle adapter (included in the package) into the neck of the bottle until a tight seal is made. Turn the bottle upside down and withdraw the prescribed amount of HETLIOZ LQ oral suspension from the bottle. Leave the press-in bottle adapter in place on bottle neck and replace cap on bottle. Store refrigerated. After opening, discard after 5 weeks (for the 48 mL bottle) and after 8 weeks (for the 158 mL bottle).
Provided are a peripheral blood TCR marker for ovarian cancer, and a detection kit and the use thereof. The marker comprises at least one protein from those shown in SEQ ID NOs: 1-100. On the basis of a high-throughput sequencing method, only a small amount of peripheral blood needs to be taken to extract RNA. An immune repertoire library is established by means of processing samples. Then, by means of high-throughput sequencing and TCR data analysis, a characteristic TCR sequence in the peripheral blood for ovarian cancer is first determined, and then test results of samples to be tested are compared with the characteristic TCR sequence, so as to determine whether one has ovarian cancer. By means of the method, a large number of specific TCR sequences of ovarian cancer can be simultaneously compared, and the method has higher specificity and accuracy compared with the separate detection of one or more markers, thereby improving the diagnostic efficiency.
At present, most studies use chemotherapy combined with cetuximab or cetuximab alone as the maintenance treatment scheme after the first-line regimen containing cetuximab. However, the skin reaction caused by cetuximab and frequent infusion treatment will bring inconvenience to patients. MACBETH study compared the maintenance of bevacizumab with cetuximab, although there was no significant difference in PFS between them, the Bev group seemed to convey a longer median OS. Fruquintinib is a highly selective anti angiogenesis TKI. This study aims to explore the efficacy and safety of fruquintinib combined with capecitabine in maintenance treatment after first-line chemotherapy combined with cetuximab. Both fruquintinib and capecitabine are orally given, so this regimen may provide a maintenance treatment option that is more manageable for patients in clinical practice.
A method for manufacturing a composition for controlled release including multiple steps is provided. Firstly, an inclusion and a polymer aqueous solution are provided. The polymer aqueous solution has weight percentage ranging from 0.4% to 2%. Then, the inclusion is mixed with the polymer aqueous solution well so as to form a mixture; a molding process is performed on the mixture to form a plurality of colloids. Next, a cross-linking process is performed to conduct a reaction between the colloids and an aqueous solution having divalent metal ion so as to form a plurality of reticular structures. Finally, a drying process is performed on the reticular structures. A composition for controlled release is also provided.
PROBLEM TO BE SOLVED: To provide compositions containing lipase for the treatment of disorders characterized by low lipase secretion.SOLUTION: The compositions includes crosslinked lipase crystals that are highly resistant to proteolysis, low pH, and elevated temperature. The invention is based in part on the discovery of compositions which include lipase in a crosslinked crystalline form that is highly resistant to proteolytic and acid degradation. Because the crosslinked crystalline lipase exhibits high stability against proteases and acid, the composition can be administered in low doses to patients suffering from gastrointestinal disorders. In one aspect, the invention provides a composition that includes a crosslinked lipase crystal, a protease, and an amylase. The lipase crystal in the composition is crosslinked with a multifunctional crosslinking agent and is preferably stable at pH 1-9. Preferably, the enzyme is active at a pH range from about 2.0 to 9.0. More preferably, the enzyme is active at pH 4-7.
Osteoarthritis (OA), the most common joint disease in humans, is a significant cause of pain and disability. Its prevalence increases with age, leading to about 65-85% of those age 65 years and older having OA. Involvement of the knee with OA is the main reason for significant functional impairment as it alters ambulation through pain and stiffness. Nonpharmacological management of knee OA includes the use of orthotic supports such as wedged insoles for varus or valgus knee deformities to relieve pain and improve function in the early stages of this joint disease. Although these interventions are desirable because they are simple and inexpensive, we do not have a clear understanding about their efficacy in relieving pain and disability in people with knee OA. We also do not know whether there is a relationship between changes in joint biomechanics that occur with wedged insoles and changes in function and progression of OA. Furthermore, information is lacking regarding which patients would benefit from wedged insoles. Answering these questions will be critically important in the development of guidelines for the prescription of wedged insoles in knee OA. Patients in this study will be evaluated at baseline and after wearing the lateral-wedged insoles immediately and after wearing the insoles for four weeks. The participants will wear lateral-wedged insoles for the painful knee(s) for as many hours and for as many days of the week as they can tolerate. Some subjects may use a neutral position insole for an asymptomatic knee.
Venous thromboembolism (VTE) is a common complication in patients with brain tumors. The management of acute VTE is particularly challenging due to an elevated risk of intracranial hemorrhage (ICH). Risk of developing ICH on anticoagulation is influenced by a number of factors including tumor type, recent surgery, concomitant medications, platelet counts, and radiographic features. In patients with a heightened risk for ICH, the benefits of anticoagulation need to be balanced against a likelihood of developing major hemorrhagic complications. Management decisions include whether to administer anticoagulation, at what dose, placement of an inferior vena cava filter, monitoring for development of hemorrhage or progressive thrombus, and escalation of anticoagulant dose. This article discusses the complexities of treating acute VTE in patients with brain tumors and outlines treatment algorithms based on the presence or absence of ICH at the time of VTE diagnosis. Through case-based scenarios, we illustrate our approach to anticoagulation, emphasizing individualized risk assessments and evidence-based practices to optimize treatment outcomes while minimizing the risks of hemorrhagic events in patients with brain tumors.
The invention refers to pharmaceutical compositions based on oil extracted from the seeds of Carapa guianensis Aubl and/or tetranortriterpenoid compound separated from the oil and bearing its bioactivity, which has following pharmacological properties:  allergy resistance, antiphlogistic activity, acesodyne and immunoregulation, reducing the side effect and lowering the cost. The medicine combination is used to treat and prevent or defend human allergy and inflammatory disease by oral or local treatment. In each case, the compound may be liquid or solid form. The inventive compound for local treatment is nontoxic or low toxicity and provided in a semi-solid type (cream). The inventive medicine combination also provides an important replacement therapy to the allergy disease such as skin and respiratory besides the effects to the different inflammation reaction to the allergen and source of infection. Therefore, the combination can treat rheumatoid, inflammation and modification process, a plurality of hurt, pain and postoperative inflammation, acute pain complex.
The "Practice-from Beginning Group" will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the "Practice-2 month Later Group". Then, after 2 weeks, the participants of "Practice-from Beginning Group" and "Practice-2 month Later Group" will crossover. The "Practice-from Beginning Group" has no intervention, but the "Practice-2 month Later Group" will practice Duo-in exercise for 2 months.
Participants will receive 240 milligram (mg) JNJ-64041575 as 6.0 milliliter (mL) of a 40-milligram per milliliter (mg/mL) current oral suspension formulation (reference 1) under fasted conditions (Treatment A) in period 1, then 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 1) under fasted conditions (Treatment B) in period 2 followed by 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 2) under fed conditions (Treatment C) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
OBJECTIVE: To evaluate whether there were differences in the presentation of patients with tubal ectopic pregnancy (EP) during the first year of the COVID-19 pandemic.
METHODS: We performed a retrospective cohort study of all cases of tubal EP between March 2019 and March 2020 (pre-pandemic) and between March 2020 and March 2021 (pandemic). We compared between these two groups the risk factors, clinical characteristics, laboratory data, sonographic aspects, treatment applied and complications.
RESULTS: We had 150 EP diagnoses during the two years studied, of which 135 were tubal EP. Of these, 65 were included in the pre-pandemic and 70 in the pandemic period. The prevalence of lower abdominal pain was significantly higher in the pandemic compared to the pre-pandemic period (91.4% vs. 78.1%, p=0.031). There was no significant difference in shock index, initial beta-hCG level, hemoglobin level at diagnosis, days of menstrual delay, aspect of the adnexal mass, amount of free fluid on ultrasound, and intact or ruptured presentation between the groups. Expectant management was significantly higher during the pandemic period (40.0% vs. 18.5%, p=0.008), surgical management was lower during the pandemic period (47.1% vs. 67.7%, p=0.023), and number of days hospitalized was lower in the pandemic period (1.3 vs. 2.0 days, p=0.003).
CONCLUSION: We did not observe a significant difference in patient history, laboratory and ultrasound characteristics. Abdominal pain was more common during the pandemic period. Regarding treatment, we observed a significant increase in expectant and a decrease in surgical cases during the pandemic period.